(Q37838346)

English

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents

scientific article published on July 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

object named as

Julia F Simard

2

0 references

object named as

Martin Neovius

3

0 references

author name string

Pauline Raaschou

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Johan Askling

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Anti-Rheumatic Therapy in Sweden Study Group

5

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

publication date

1 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1812-1822

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

TNF-alpha in promotion and progression of cancer

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Autoimmune and inflammatory disorders and risk of malignant lymphomas--an update

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Swedish registers to examine drug safety and clinical issues in RA.

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

The completeness of the Swedish Cancer Register: a sample survey for year 1998.

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Ten years with biologics: to whom do data on effectiveness and safety apply?

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data

1 reference

https://api.crossref.org/works/10.1002%2FART.30247

21 January 2018

Identifiers

10.1002/ART.30247

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37838346&oldid=2174853638"